APLM
Bullish signalScored 2026-09-06 Drivers: fundamentals. Moteurs : fondamentaux.
Research, not advice.
À propos
Apollomics, Inc.
- Nom
- Apollomics, Inc.
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $63.7M
- Employés
- 14
- PDG
- Hung-Wen Chen
- Site web
- https://www.apollomicsinc.com
- Marché
- ADAPANLATHABLRXGOVXICU
Apollomics, Inc., a biotechnology enterprise established in 2015 and headquartered in Foster City, California, conducts its research and development operations across California, Hangzhou, Shanghai, China, and Australia. The company is dedicated to discovering and advancing innovative oncology treatments to address critical unmet medical requirements. Its therapeutic pipeline features APL-101 (Vebreltinib), a potent and selective c-Met inhibitor being developed for non-small cell lung cancer and other advanced malignancies. Also in development is APL-102, an orally administered, small molecule multiple tyrosine kinase inhibitor intended for liver, breast, and esophageal cancers. Furthermore, APL-122 is an investigational tumor inhibitor candidate focused on treating cancers within the brain. The organization was formerly known as CBT Pharmaceuticals, Inc. before adopting the name Apollomics, Inc. in January 2019.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
ACHAT TOTAL: 130000 titres (~1950000 USD)
- Insiders
- Chen Hung-WenLIN PETER KUAN-HOW
- Total bought
-
$1,950,000
Avg buy (VWAP, 90d window) $12.41 vs last close —
- Total sold
-
—
Avg sell (VWAP, 90d window) —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- 2026-08-14
- Last synced
-
2026-08-21 23:36:53
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-08-14 | Chen Hung-Wen | Buy · P | 166,667 | $12.00 | $2,000,004 | Form 4 |
| 2026-08-14 | LIN PETER KUAN-HOW | Buy · P | 26,667 | $15.00 | $400,005 | Form 4 |
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Bullish signalScored 2026-09-06 Drivers: fundamentals. Moteurs : fondamentaux.
APLM presents a meaningful insider cluster buy signal (~$1.95M, 130k shares) following a $10M private placement, suggesting insiders may see a near-term clinical runway extension — however, this catalytic confidence…
The first sentence of the analysis written for APLM on 2026-09-06 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Supports a bullish reading. Open-market purchases outweigh sales
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Pulls against a bullish reading. Current ratio 0.96 · operating margin -111%
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 97.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Ebit Margin | -111.4% | -20771.2% | -6522.4% | -13642.4% | -2513500.0% | |
| Ebitda Margin | -108.4% | -20734.8% | -6509.9% | -13586.1% | -2505850.0% | |
| Operating Profit Margin | -111.4% | -21280.8% | -6578.9% | -13957.0% | -2542850.0% | |
| Pretax Profit Margin | -128.7% | -27070.2% | -21022.0% | -74554.2% | -4739800.0% | |
| Continuous Operations Profit Margin | -128.7% | -27201.0% | -21023.3% | -74554.5% | -4739850.0% | |
| Net Profit Margin | -128.7% | -27201.0% | -21023.3% | -74554.5% | -4739850.0% | |
| Bottom Line Profit Margin | -128.7% | -27201.0% | -21023.3% | -74554.5% | -4739850.0% | |
| Current Ratio | 0.957 | 1.388 | 2.945 | 4.515 | 7.330 | |
| Quick Ratio | 0.957 | 1.388 | 2.945 | 4.515 | 7.164 | |
| Solvency Ratio | -1.079 | -6.532 | -12.188 | -0.459 | -0.281 | |
| Cash Ratio | 0.518 | 1.320 | 2.365 | 2.644 | 3.448 | |
| Price To Earnings Ratio | -2.470 | -0.185 | -0.416 | -16.818 | -42.345 | |
| Price To Earnings Growth Ratio | 0.029 | 0.002 | -0.002 | -0.103 | -3.187 | |
| Forward Price To Earnings Growth Ratio | 0.029 | 0.002 | -0.002 | -0.103 | -3.187 | |
| Price To Earnings Diluted Ratio | -2.470 | -0.185 | -0.416 | -16.818 | -42.345 | |
| Price To Earnings Diluted Growth Ratio | 0.029 | 0.002 | -0.002 | -0.103 | -3.187 | |
| Price To Book Ratio | -8.476 | 1.857 | 1.741 | -2.007 | -4.049 | |
| Price To Sales Ratio | 3.179 | 45.622 | 87.446 | 2,783.915 | 430,941.147 | |
| Price To Free Cash Flow Ratio | -2.606 | -0.314 | -1.661 | -20.819 | -16.946 | |
| Price To Operating Cash Flow Ratio | -2.606 | -0.314 | -1.662 | -20.998 | -19.899 | |
| Debt To Assets Ratio | 0.096 | 0.074 | 0.084 | 0.013 | 2.636 | |
| Debt To Equity Ratio | -0.202 | 0.199 | 0.113 | -0.002 | -1.529 | |
| Debt To Capital Ratio | -0.253 | 0.166 | 0.102 | -0.002 | 2.891 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 2.947 | |
| Financial Leverage Ratio | -2.106 | 2.693 | 1.343 | -0.171 | -0.580 | |
| Working Capital Turnover Ratio | 6.556 | 0.014 | 0.024 | 0.005 | 0.000 | |
| Operating Cash Flow Ratio | -1.639 | -3.885 | -3.187 | -3.466 | -3.195 | |
| Operating Cash Flow Sales Ratio | -1.220 | -145.167 | -52.630 | -132.582 | -21,656.000 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | 1.001 | 1.000 | 1.009 | 1.174 | |
| Debt Service Coverage Ratio | -141.862 | -230.804 | -12.188 | -471.871 | -22.394 | |
| Interest Coverage Ratio | -145.738 | -235.397 | -360.087 | -484.742 | -612.735 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | -10.200 | 0.000 | -20.098 | |
| Operating Cash Flow Coverage Ratio | -16.126 | -29.755 | -9.270 | -43.213 | -0.133 | |
| Capital Expenditure Coverage Ratio | 0.000 | -1,197.625 | -7,201.500 | -116.687 | -5.737 | |
| Dividend Paid And Capex Coverage Ratio | 0.000 | -1,197.625 | -7,201.500 | -116.687 | -5.737 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -2.646 | -0.006 | -0.831 | -19.769 | -22.758 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 97.0% | ▼-3.0% | ▼-2.4% |
| Ebit Margin | -111.5% | ▲20659.8% | ▲510798.0% |
| Ebitda Margin | -108.5% | ▲20626.4% | ▲509249.4% |
| Operating Profit Margin | -111.5% | ▲21169.4% | ▲516844.2% |
| Pretax Profit Margin | -128.7% | ▲26941.5% | ▲972386.4% |
| Continuous Operations Profit Margin | -128.7% | ▲27072.3% | ▲972422.8% |
| Net Profit Margin | -128.7% | ▲27072.3% | ▲972422.8% |
| Bottom Line Profit Margin | -128.7% | ▲27072.3% | ▲972422.8% |
| Current Ratio | 0.957 | ▼-0.431 | ▼-2.470 |
| Quick Ratio | 0.957 | ▼-0.431 | ▼-2.437 |
| Solvency Ratio | -1.079 | ▲5.453 | ▲3.029 |
| Cash Ratio | 0.518 | ▼-0.802 | ▼-1.541 |
| Price To Earnings Ratio | -2.470 | ▼-2.286 | ▲9.977 |
| Price To Earnings Growth Ratio | 0.029 | ▲0.026 | ▲0.681 |
| Forward Price To Earnings Growth Ratio | 0.029 | ▲0.026 | ▲0.681 |
| Price To Earnings Diluted Ratio | -2.470 | ▼-2.286 | ▲9.977 |
| Price To Earnings Diluted Growth Ratio | 0.029 | ▲0.026 | ▲0.681 |
| Price To Book Ratio | -8.476 | ▼-10.333 | ▼-6.289 |
| Price To Sales Ratio | 3.179 | ▼-42.443 | ▼-86769.083 |
| Price To Free Cash Flow Ratio | -2.606 | ▼-2.292 | ▲5.863 |
| Price To Operating Cash Flow Ratio | -2.606 | ▼-2.292 | ▲6.490 |
| Debt To Assets Ratio | 0.096 | ▲0.022 | ▼-0.485 |
| Debt To Equity Ratio | -0.202 | ▼-0.400 | ▲0.083 |
| Debt To Capital Ratio | -0.253 | ▼-0.418 | ▼-0.833 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | ▼-0.589 |
| Financial Leverage Ratio | -2.106 | ▼-4.799 | ▼-2.342 |
| Working Capital Turnover Ratio | 6.556 | ▲6.543 | ▲5.237 |
| Operating Cash Flow Ratio | -1.639 | ▲2.246 | ▲1.435 |
| Operating Cash Flow Sales Ratio | -1.220 | ▲143.947 | ▲4396.300 |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | ▼-0.001 | ▼-0.037 |
| Debt Service Coverage Ratio | -141.862 | ▲88.943 | ▲33.962 |
| Interest Coverage Ratio | -145.738 | ▲89.658 | ▲222.001 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | ▲6.060 |
| Operating Cash Flow Coverage Ratio | -16.126 | ▲13.629 | ▲3.573 |
| Capital Expenditure Coverage Ratio | 0.000 | ▲1197.625 | ▲1704.310 |
| Dividend Paid And Capex Coverage Ratio | 0.000 | ▲1197.625 | ▲1704.310 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -2.646 | ▼-2.640 | ▲6.556 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $27.0M | $9.0M | $71.8M | $899.2M | $861.9M | |
| Enterprise value | $24.4M | $233K | $44.4M | $867.5M | $1.14B | |
| EV / Sales | 2.87x | 1.18x | 54.08x | 2685.82x | 570274.15x | |
| EV / Op. cash flow | -2.35x | -0.01x | -1.03x | -20.26x | -26.33x | |
| EV / Free cash flow | -2.35x | -0.01x | -1.03x | -20.09x | -22.42x | |
| EV / EBITDA | -2.65x | -0.01x | -0.83x | -19.77x | -22.76x | |
| Net debt / EBITDA | 0.29x | 0.21x | 0.51x | 0.72x | -5.56x | |
| Current ratio | 0.96x | 1.39x | 2.94x | 4.51x | 7.33x | |
| Income quality | 0.95x | 0.54x | 0.25x | 0.18x | 0.46x | |
| Graham net-net | -$3 | $2 | $32 | -$541 | -$277 | |
| Tax burden | 100.0% | 100.5% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 115.4% | 130.3% | 322.3% | 546.5% | 188.6% | |
| Working capital | -$275K | $2.9M | $26.4M | $43.4M | $85.8M | |
| Invested capital | $305K | $5.6M | $41.7M | $59.7M | $101.9M | |
| Return on assets | -162.9% | -411.2% | -311.6% | -314.9% | -76.8% | |
| Operating ROA | -95.6% | -123.1% | -81.9% | -45.1% | -34.7% | |
| Return on tangible assets | -162.9% | -474.1% | -424.8% | -390.3% | -87.3% | |
| Return on equity | 343.1% | -1107.3% | -418.6% | 53.7% | 44.5% | |
| Return on invested capital | -1586.8% | -710.3% | -116.8% | -69.6% | -45.2% | |
| Return on capital employed | -2441.5% | -739.4% | -129.1% | -70.3% | -46.3% | |
| Earnings yield | -40.5% | -596.2% | -240.4% | -26.8% | -11.0% | |
| Free cash flow yield | -38.4% | -318.5% | -60.2% | -4.8% | -5.9% | |
| Capex / Op. cash flow | 0.0% | -0.1% | -0.0% | -0.9% | -17.4% | |
| Capex / Depreciation | 0.0% | 6.6% | 0.9% | 47.4% | 1108.7% | |
| Capex / Sales | 0.0% | 12.1% | 0.7% | 113.6% | 377500.0% | |
| SG&A / Sales | 146.4% | 8973.7% | 2514.1% | 3079.6% | 764550.0% | |
| R&D / Sales | 65.1% | 12407.1% | 4164.8% | 10977.4% | 1778400.0% | |
| Stock comp / Sales | -11.5% | 5518.2% | 1545.1% | 1109.0% | 406100.0% | |
| Intangibles / Total assets | 0.0% | 13.3% | 26.6% | 19.3% | 12.0% | |
| Days sales outstanding | 107d | 234d | 207d | 618d | 92345d | |
| Days payables outstanding | 0d | 0d | 0d | 0d | 0d | |
| Operating cycle | 107d | 234d | 207d | 618d | 92345d | |
| Cash conversion cycle | 107d | 234d | 207d | 618d | 92345d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-08-11 Apollomics Announces $10 Million Private Placement Transaction FOSTER CITY, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM ) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced that it has entered into definitive subscription agreements (the “Subscription Agreements”) for a private placement transaction (the “Private Placement”) with certain accredited investors (the “Investors”), for an aggregate gross consideration of approximately $10.0 million. The Private Placement is expected to close on or about August 14, 2026, subject to the satisfaction of customary closing conditions.
- 2026-07-13 Apollomics Regains Full Compliance with Nasdaq Listing Requirements FOSTER CITY, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM ) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced that on July 8, 2026, it received written notice from the Nasdaq Listing Qualifications Staff (Staff) stating that the Company regained compliance with the Market Value of Listed Securities (MVLS) requirement, as set forth in Nasdaq Listing Rule 5550(b)(2) (Rule) for continued listing on the Nasdaq Capital Market, and the matter is now closed.
- 2026-06-24 Apollomics Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement and Updates Rights for Vebreltinib (APL-101) in Asia FOSTER CITY, Calif., June 24, 2026 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM ) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced that it has received a notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) dated June 18, 2026 stating that the Company is not in compliance with the requirement to maintain a minimum Market Value of Listed Securities (“MVLS”) of $35 million as set forth under Nasdaq Listing Rule for continued listing on The Nasdaq Capital Market.